

T-11012/04/2011-NACO/BSD-ICTC(PF)

Government of India
Ministry of Health and Family Welfare
National AIDS Control Organization
(Basic Service Division)

6th & 9th Floor Chandralok Building
36 Janpath, New Delhi
Date: 15th May 2023

Subject: Technical Specifications of STI Colour Coded drug kit, Dual test kit HIV & Syphilis and Condom-reg.


This is in reference to review and revise the Technical Specifications of commodities procured and used under NACP V. (STI colour coded drug kits, Dual kit HIV & Syphilis and Condom)

The meeting of the technical specification Committee held under the **Chairpersonship of Dr. Sunil Gupta, Principal Consultant, NCD, on 04th May 2023 from 2:30 pm onwards** at 9th floor committee hall NACO office Janpath, Delhi. The agenda of the meeting is enclosed with the letter for your reference.

In this context, **Approved Technical Specification of STI Colour Coded drug kit, Dual test kit HIV & Syphilis and Condom** are enclosed herewith for your reference.

This issues with the approval of the competent authority.

Dr. Bhawani Singh


15.05.2023
(DD BSD & TI)

To,

1. All Project Directors, SACS

Copy to:

- 1 PPS to AS & DG NACO
2. PS to Director, NACO
3. All HODs/ADG/DDs NACO

Minutes of Meeting Technical Specification Committee, NACO for review and revision of specifications of the programmatic commodities under BSD and STI components of NACP

Date: 04th May 2023

Venue: NACO Office/ virtual cum physical

A Meeting of Technical Specification Committee of NACO for Commodities under the BSD & STI division was convened under the Chairpersonship of Dr. Sunil Gupta, Principal Consultant, NCDC, Government of India, on 04th May 2023 via hybrid mode at 9th floor committee Room, NACO.

At the outset, chairperson gave the opening remarks and set the context for meeting and briefed the agenda points.

- Agenda 1: Review & approval of Technical Specification for STI colour Coded Kits
- Agenda 2: Review & approval of Technical Specifications for Dual Test Kit for HIV & syphilis
- Agenda 3: Review & approval of Technical Specifications for Condoms
- Agenda 4: Any other point of discussion with the permission of chair

All members were present and quorum was complete. Participant list is placed at Annexure 1. After due discussions and deliberations, the committee approved the technical specifications as detailed Agenda wise.

Agenda 1:

Technical Specification of Pre – Packed Colour Coded STI/ RTI drug kits

Background: This with the inputs received from DGCI in last technical specification committee meeting held on 02 March 2022, is "" kits are not approved by CDSCO except the treatment kit 5, i.e. Acyclovir 400mg tablet" & "it should be licenced under the Drugs & Cosmetic Act & rules made there under. The matter was deliberated in the meeting and the revision in technical specifications of pre packed colour coded STI/RTI drug kits was done, is as follows:

KIT Description:

S. No.	Colour	Description of Kit	Unit
1	Grey	Tab Azithromycin 1 gm and Tab Cefixime 400 mg	One Tablet of each drug in one kit
2	Green	Tab Secnidazole 1 gm and Tab Fluconazole 150 mg	Two Tablets of Secnidazole and One Tablet of Fluconazole
4	Blue	Cap/tab Doxycycline 100 mg and Tab Azithromycin 1 gm	Thirty Tablets of Doxycycline and One Tablet of Azithromycin in each drug in one kit
5	Red	Tab Acyclovir 400 mg	Twenty one tablets of drug in one kit
6	Yellow	Tab Cefixime 400 mg and Tab Metronidazole 400 mg and Cap/Tab Doxycycline 100 mg	One tablet of Cefixime and Twenty Eight Tablets of Metronidazole and Doxycycline each drug in one kit
7	Black	Cap/Tab Doxycycline 100 mg and Tab Azithromycin 1 gm	Forty Two Tablets of Doxycycline and One tablet of Azithromycin in each drug in one kit
3	White	Inj. Benzathine Penicillin 2.4 MU with equal number of sterile water 10 ml	Vial
3	White	Tab Azithromycin 1 gm	Tablet
3	White	Disposable syringe 10 ml with disposable needle	Number

product Code Number	Product Name (Generic)	Pharmacopeia standards	Strength	Dosage Form	Number of generic product per each kit	Product Description
Product code 1: STI/RTI treatment kit 1 for UD; ARD and Cervicitis, PT	Azithromycin	I.P.	1 gm	Tablet	1	Treatment kit 1 for UD; ARD and Cervicitis, PT. Colour of Pouch is Grey (25%).
	Cefixime	I.P.	400 mg	Tablet	1	
Product code 2: STI/RTI treatment kit 2 for Vaginitis	Secnidazole	I.P.	1 gm	Tablet	2	Treatment kit 2 for Vaginitis. Colour of Pouch is Green.
	Fluconazole	I.P.	150 mg	Capsule / Tablet	1	
Product code 3: STI/RTI treatment kit 3 for GUD (Genital Ulcer Diseases)	Azithromycin	I.P.	1 gm	Tablet	1	Treatment kit 3 for GUD (Genital Ulcer Diseases) . Colour of Pouch is White.
	Benzathine Penicillin	I.P.	2.4 MU	Vial	1	
	Disposable Syringe	-	10 ml capacity	NA	1	
	Disposable Needle	-	21 gauze	NA	1	
	Distilled Water	I.P.	10 ml	Plastic Phial	1	
Product code 4: STI/RTI treatment kit 4 for GUD (Genital Ulcer Diseases)	Azithromycin	I.P.	1 gm	Tablet	1	Treatment kit 4 for GUD (Genital Ulcer Diseases) . Colour of Pouch is Blue.
	Doxycyclin	I.P.	100 mg	Capsule / Tablet	30	
Product code 5: STI/RTI treatment kit 5 for	Acyclovir	I.P.	400 mg	Tablet	21	Treatment kit 5 for GUD (Genital Ulcer

GUD (Genital Ulcer Diseases)						Diseases) . Colour of Pouch is Red.
Product code 6: STI/RTI treatment kit 6 for LAP (Lower Abdomin al Pain)	Cefixime	I.P.	400 mg	Tablet	1	Treatment kit 6 for LAP. Colour of Pouch is Yellow.
	Doxycycline	I.P.	100 mg	Capsul e / Tablet	28	
	Metronidazol e	I.P.	400 mg	Tablet	28	
Product code 7: STI/RTI treatment kit 7 for IB (Inguinal Bubo)	Azithromycin	I.P.	1 gm	Tablet	1	Treatment kit 7 for IB. Colour of Pouch is Black.
	Doxycycline	I.P.	100 mg	Capsul e / Tablet	42	

Note: For ease of procurement, the individual components of Kit 3 may be procured separately conforming to the colour code.

General Specifications:

1. Product specifications indicate dosage form (e.g. tablet, liquid, injectable, emulsion, suspension etc.) and the drug content (exact number of mg or percentage v/v with acceptable range).
2. Product shall be licenced by the competent authority under Drugs & Cosmetic Act & rules made there under.
3. The products should conform to standards specified in Indian Pharmacopoeia.
4. Not only the pharmaceuticals or vaccine items, but also the packaging components (bottles and closures) should also conforms to specifications suitable for use in a climate similar to that prevailing in the country of the purchaser. All packaging must be properly sealed and tamper-proof.
5. The manufacture should obtain and submit the license issued by the competent authority under Drugs & Cosmetic Act and rules there under for the packaging of the drug kits from concerned drug control authorities.
6. Pharmaceuticals requiring refrigeration or freezing for stability must specifically indicate storage requirements on labels and containers and be shipped in the special containers to ensure stability in transit from point of shipment to the port of entry.
7. All product must indicate the date of manufactures and expiry.
8. All products must arrive at the consignee point with a remaining shelf life of at least five-sixths ($5/6^{\text{th}}$) of the total stipulated shelf life at the time of manufacture.
9. Shelf life of the various drugs would be as follows:
 - a) Azithromycin: shelf life should not be less than 36 months from the date of manufacture.
 - b) Cefixime: shelf life should not be less than 36 months from the date of manufacture.
 - c) Acyclovir: shelf life should not be less than 36 months from the date of manufacture.
 - d) Doxycycline: shelf life should not be less than 36 months from the date of manufacture.
 - e) Fluconazole: shelf life should not be less than 36 months from the date of manufacture.
 - f) Secnidazole: shelf life should not be less than 36 months from the date of manufacture.
 - g) Metronidazole: shelf life should not be less than 36 months from the date of manufacture.
 - h) Benzathine Penicillin: shelf life should not be less than 24 months from the date of manufacture.
 - i) Distilled Water of Water for Injection: shelf life should not be less than 24 months from the date of manufacture.

Labelling Instructions:

1. The label for each product shall comply with Drugs and Cosmetics Act and Rules made there under and include:
 - a) The INN or generic name prominently displayed and above the brand name, where a brand name has been given. Brand names should not be bolder or larger than the generic name.
 - b) The active ingredient per unit dose, tablet or capsule etc.
 - c) The applicable pharmacopeia standards.
 - d) Content per pack.
 - e) Special storage requirements.
 - f) Batch number and
 - g) Date of manufacture and date of expiry of individual components as well as the kit
 - h) The manufacturing license number of individual drug components as well as the drug kit
 - i) Colour coding as mentioned in schedule of requirement.
2. The outer case or carton should also display the above information.

Case Identification:

1. All cases should prominently indicate the following:
 - a) Purchaser's line and code numbers.
 - b) The generic name of the product, if any
 - c) Date of manufacture and expiry (in clear language not code)
 - d) Batch number
 - e) Quantity per case.
 - f) Special instructions for storage.
 - g) Name and address of manufacturer with license number.
 - h) Any addition cautionary statements.
2. No case should contain kits from more than one batch.

General requirements for standards and Quality Assurance requirements:

All products must **conform** to specifications, meet the requirements of the manufacturing legislations and regulations of pharmaceuticals in the country of origin and must undergo strict raw material inspection, in process checks, appropriate material handling to eliminate cross contamination (of molecules) and final product testing to ensure quality and consistency of the products.

With each consignment, a certificate of quality assurance test results concerning quantitative assay, chemical analysis, sterility, pyrogenic quantity uniformity, microbial limit and other tests as applicable to the product being supplied must be provided.

Special Instructions:

1. Each kit, inner carton and nested cartons to have the following words printed **DIAGONALLY ACROSS THE LABEL** in the red ink with bold letters.

"GOVERNMENT OF INDIA SUPPLY – NOT FOR SALE"

The supplier should also ensure marking of unique number on each kit, inner carton and nested cartons.

2. Life of the product, indicating the date of manufacture and date of expiry should be printed as per Drug & Cosmetic Act – India.
3. Equivalency of standards and codes:

Wherever reference is made in the Technical Specifications to specific standards and codes to be met by the product to be furnished or tested, the provisions of the latest current edition or revision of the relevant standards or codes in effect shall apply, unless otherwise expressly stated in the contract. Where such standards and codes are national or authoritative standards that ensure substantial equivalence to the standards and codes specified will be acceptable.

4. Packaging Instruction: The supplier will have to make unit packing for each kit. Each unit package will be marked on three sides with proper paints / indelible ink, the following:
 - a) Project
 - b) Purchase order number
 - c) Country of origin of Goods
 - d) Supplier's name and
 - e) Packaging list reference number
5. Each outer packing containing the unit packing should have the following label printed in bold letters in large size.
 - a) Purchaser's name
 - b) Project
 - c) Purchase order no
 - d) Country of origin of Goods
 - e) Supplier's Name

Specification of Packaging Material:

General Specifications:

- a) The blister is TROPICALIZED with moisture barrier properties for drug stability under field condition.
- b) Quality Assurance is according to Norms ISO 9001/EN 2901 of aluminium-foil.
- c) Standard coloured BCP's.
- d) Spacing between tablets allowing removal by patients with finger deformities.
- e) Complete with self-adhesive patient labels.
- f) Outside kit label with health care instructions, if any, colour coded.
- g) Perforation and folding lines, to allow the packet use.
- h) The pharmaceuticals under product codes 1, 2, 3, 4, 5, 6 & 7 will be supplied as blister pack separately for each pharmaceuticals product and duly packed in pre specified laminated colour coded kits which thereafter would be packed in Millboard/grey board boxed, 20 kits per box.

These Millboard/grey board boxes would be put in 5-ply respective shippers for dispatch. The Kit no.3 containing pharmaceuticals (a tablet and an injection) under product code 7 will have separately Schedule 1 and Schedule 5 in same colour coded kit.

Complex constructions with PVC films

Rigid PVC film thermo formable

XX

Polyethylene

XX

Polyvinylidene chloride compound with particularly high water vapour barrier.

Handwritten signatures and initials in blue ink, including a large signature at the bottom left, a signature at the bottom center, and several initials and marks scattered in the middle and right sections of the page.

Technical Specification data for the Standards Complexes

Complex:

Rigid PVC film gauge (Microns)	200
PE coating (Microns)	25
PVDC coating (gsm)	60
Total weight (gsm)	356
Complex gauge (mm)	0.280

Water Vapour Transmission Rate (W.V.T.R.)

Thermoformed:

20°C, 85% r.h., gsm/24 h 0.15

38°C, 90% r.h. , gsm/24 h 0.7

Not Thermoformed:

20°C, 85% r.h., gsm/24 h 0.06


38°C, 90% r.h. , gsm/24 h 0.4

Shrinkage longitudinally

T = 140°C, t = 20 min. (%) 5-6

Application temperature (C) 68-74

r.h. = relative humidity



ms
60/1
R

[Handwritten signatures]



KIT 3

Tablet Azithromycin 1 gm single dose
For
GENITAL ULCER DISEASE
(Non-HERPETIC SYNDROME)

Not to be used alone.
To be used along with Injection Benzathine Penicillin 2.4 million units
with equal number of vials of sterile water for injection 10ml.

IMPORTANT
NON-COMMERCIAL PRODUCT
NOT FOR SALE
TO BE DISPENSED ONLY AT RTVSTI
CLINICS

Manufactured in India by

Each film coated tablet contains:
Azithromycin (As Dihydrate) IP
Eq. to Azithromycin Anhydrous..... 1 gm
Excipients.....q. s.
Colour: Titanium Dioxide IP

Dosage : As directed by the Physician.

**Storage: Store protected from light & moisture,
at a temperature not exceeding 30°C.**

Keep out of reach of children.

Mfg. Lic. No.: G/28/967

Warning: Allergic type of cholestatic hepatitis and abnormalities
of liver function tests may be associated with Azithromycin when used for
more than two weeks or in repeated course. These changes are reversible
when drug is discontinued.

CAUTION Not to be sold by retail without the prescription
of a Registered Medical Practitioner.

Batch No.:

Mfg. Date:

Exp. Date:

GOVERNMENT OF INDIA NACO SUPPLY NOT FOR SALE

Size : L-95 x H-140 mm

Front

Back



KIT 4

Doxycycline 100 mg BID for 15 days +
Azithromycin 1 gm Single dose

For
GENITAL ULCER DISEASE-NON-HERPETIC
SYNDROME

Manufactured in India by

IMPORTANT
NON-COMMERCIAL PRODUCT NOT FOR SALE
TO BE DISPENSED ONLY AT STI/RTI CLINICS

R

EACH KIT CONTAINS
D - DOXYCYCLINE HYDROCHLORIDE 30 Capsules
CAPSULES I.P. 100 mg
Each Capsule Contains
Doxycycline Hydrochloride I.P. 100 mg
Eq. to Doxycycline 100 mg
Excipients q. s.

A - AZITHROMYCIN TABLETS I.P. 1 gm 1 Tablet
Each Film Coated Tablet Contains
Azithromycin Dihydrate IP 1 gm
Eq. to Azithromycin Anhydrous 1 gm
Excipients q. s.
Colour: Titanium Dioxide IP

Store protected from light and
moisture at a temperature not exceeding 30°C.
Keep medicine out of reach of children.

Warning: Allergic type of cholestatic hepatitis and abnormalities of liver
function tests may be associated with Azithromycin when used for
more than two weeks or in repeated course. These changes are
reversible when drug is discontinued.

SCHEDULE H DRUG - Warning: To be sold by retail on the
prescription of a Registered Medical Practitioner only.

Mfg. Licence No. G-256

Batch No.

Mfg. Date


Exp. Date

GOVERNMENT OF INDIA NACO SUPPLY NOT FOR SALE

Size : L-95 x H-140 mm

Front

Back



KIT 5

ACYCLOVIR 400 MG TID FOR 7 DAYS

For
**GENITAL ULCER DISEASE - HERPETIC
(GUD - HERPETIC) SYNDROME**

Manufactured in India by

**IMPORTANT
NON-COMMERCIAL PRODUCT NOT FOR SALE
TO BE DISPENSED ONLY AT ST/RTI CLINICS**

Rx 21 Tablets

ACYCLOVIR TABLETS I.P. 400 mg

Each uncoated tablet contains:
Acyclovir I.P. 400 mg
Excipients q.s.

Store protected from light.
Keep medicine out of reach of children.

SCHEDULE 'H' DRUG :
Warning : To be sold by retail on the prescription of a Registered Medical Practitioner only

Mfg Licence No: G/524

Batch No.

Mfg. Date


Exp. Date

GOVERNMENT OF INDIA NACO SUPPLY NOT FOR SALE

Size : L-100 x H-160 mm

Front

Back



KIT 6

**Cefixime 400 mg Single dose &
Metronidazole 400 mg BID for 14 days & +
Doxycycline 100 mg BID for 14 days**

For
LOWER ABDOMINAL PAIN SYNDROME

Manufactured in India by

**IMPORTANT
NON-COMMERCIAL PRODUCT NOT FOR SALE
TO BE DISPENSED ONLY AT ST/RTI CLINICS**

Rx

EACH KIT CONTAINS :

C = CEFIXIME TABLETS I.P. 400 mg 1 Tablet

Each Film coated Tablets Contains
Cefixime I.P. as Trihydrate 400 mg
eq.to. Anhydrous Cefixime
Excipients q.s.
Coatant: Titanium Dioxide

M = METRONIDAZOLE TABLETS I.P. 400 mg 28 Tablets

Each Uncoated Tablets Contains
Metronidazole I.P. 400 mg
Excipients q.s.

D = DOXYCYCLINE HYDROCHLORIDE CAPSULES I.P. 100 mg 28 Capsules

Each Capsules Contains
Doxycycline Hydrochloride I.P.
Eq. to Doxycycline 100 mg
Excipients q.s.

Store protected from light and moisture at a temperature not exceeding 30°C.
Keep medicine out of reach of children.

Warning: Metronidazole has been shown to be carcinogenic in mice and rats. Unnecessary use of the drug should therefore be avoided.

"SCHEDULE H1 DRUG-WARNING:
- It is dangerous to take this preparation except in accordance with the medical advice.
- Not to be sold by retail without the prescription of a Registered medical Practitioner."

Mfg Licence No: Q/256 & G/524

C M D

Batch No.

Mfg. Date

Exp. Date

GOVERNMENT OF INDIA NACO SUPPLY NOT FOR SALE

A

Gina

MS

A

A

Size : L-100 x H-160 mm

Front

Back



KIT 7

**Doxycycline 100 mg BID for 21 days &
Azithromycin 1 gm Single dose**

**For
INGUINAL BUBO SYNDROME**

Manufactured in India by

**IMPORTANT
NON-COMMERCIAL PRODUCT NOT FOR SALE
TO BE DISPENSED ONLY AT STI/RTI CLINICS**

R

EACH KIT CONTAINS

D = DOXYCYCLINE HYDROCHLORIDE

CAPSULES I.P. 100 mg

42 Capsules

Each Capsule Contains

Doxycycline Hydrochloride I.P.

Eq. to Doxycycline 100 mg

Excipients q.s.

A = AZITHROMYCIN TABLETS I.P. 1 gm

1 Tablet

Each Film Coated Tablet Contains

Azithromycin Dihydrate I.P.

eq. to Azithromycin Anhydrous 1 gm

Excipients q.s.

Colour: Tanish Orange I.P.

Store protected from light and

moisture at a temperature not exceeding 30°C.

Keep medicine out of reach of children.

Warning: Allergic type of cholestatic hepatitis and abnormalities of liver function tests may be associated with Azithromycin when used for more than two weeks or in repeated course. These changes are reversible when drug is discontinued.

SCHEDULE H DRUG: Warning: To be sold by retail on the prescription of a Registered Medical Practitioner only.

Mfg Licence No: G256

	D	A
Batch No.		
Mfg. Date		
Exp. Date		

GOVERNMENT OF INDIA NACO SUPPLY NOT FOR SALE

[Handwritten signature]

[Handwritten signature]

[Handwritten signature]

STI/RTI kit -1: Packing specification

a. Blister Packed drugs

PVC film: Transparent, food grade, blister forming PVC film as specified

Aluminium foil: 0.025 mm, VMCH coated aluminium printed as per approved artwork

b. One laminated kit will be required (either solely or adjuvant) with other essential drugs but kept separately) for each category of STI/RTI treatment as specified in schedule of requirement.

The kit will be in Grey (25%) colour and labelled as per details given under labels

Laminated material Glassine Paper (40gm) Aluminium (9um)/Poly (150 gauze)

Type of kit –Gusseted

Each kit will contain one (1) tablet each of Azithromycin and Cefixime separately each in its own blister pack for use by one patient.

c. Millboard /Grey Board box:

Board: at least 3mm corrugated card board is to be used, surrounded on inside and outside by tightly affix millboard of at least 40gsm.

Style of: Top and bottom tuck-in flap type

The millboard box should be labelled in Grey as given under para 9.4.5.1-Labels

Each millboard box contains 20 colour coded kits

d. Five ply shipper: Each shipper will contain 20milliboard/grey board/boxes and in Grey (25%).Colour labelled as per details given under labels.

Description: RSC(Universal), type-5ply corrugated box made in narrow flute from (150)5gsm, virgin quality 'A' grade Kraft paper.

STI /RTI KIT-2 Packing specification

- a) Blister packed drugs
PVC film: Transparent, food grade, blister forming PVC film as specified
Aluminium foil: 0.025 mm, VMCH coated aluminium foil printed as per approved artwork
- b) One laminated kit will be required (either solely or as an adjuvant with other essential drugs but kept separately) for each category of STI/RTI treatment as specified in schedule of treatment.
The kit will be in green colour as per details given under Labels.
Laminated material Glassine Paper (40gm) Aluminium (9um)/Poly (150 gauze)
Type of kit –Gusseted
Each kit will contain two (2) tablets of Secnidazole 1gm each and one tablet/capsule of Fluconazole 150mg for single usage for one patient.
- c) Millboard /Grey Board box:
Board: at least 3mm corrugated cardboard is to be used, surrounded on inside and outside by tightly affix millboard of at least 400gsm.
Style of kit: Top and bottom tuck-in flap type.
The millboard box should be labelled in green colour labels as given under para 9.4.5.1-Labels
Each millboard box contains 20 colour coded kits
- d) Five ply shipper: Each shipper will contain 20boxes made of millboard / greybeard boxes and in and in Green Colour as per details given under labels.
Description: RSC(Universal), type-5ply corrugated box made in narrow flute from (150)5gsm, virgin quality 'A' grade Kraft paper.

STI /RTI KIT-3 Packing specification

a) Blister packed drugs

PVC film: Transparent, food grade, blister forming PVC film as specified

Aluminium foil: 0.025 mm, VMCH coated aluminium foil printed as per approved artwork

b) One laminated kit will be required (either solely or as an adjuvant with other essential drugs but kept separately) for each category of STI/RTI treatment as specified in schedule of treatment.

The kit will be in white colour as per details given under Labels.

Laminated material Glassine Paper (40gm) Aluminium (9um)/Poly (150 gauze)

Type of kit –Gusseted

Each kit will contain one (1) tablets of Azithromycin one gram (1gm).

c) Millboard /Grey Board box:

Board: at least 3mm corrugated cardboard is to be used, surrounded on inside and outside by tightly affix millboard of at least 400gsm.

Style of kit: Top and bottom tuck-in flap type.

The millboard box should be labelled in white colour labels as given under para 9.4.5.1-Labels

Each millboard box contains 20 colour coded kits

d) Five ply shipper: Each shipper will contain 20boxes made of millboard boxes and in and in white Colour as per details given under labels.

Description: RSC(Universal), type-5ply corrugated box made in narrow flute from (150)5gsm, virgin quality 'A' grade Kraft paper.

STI/RTI KIT -4 Packing specification

- a. Blister packed drugs
PVC film: Transparent, food grade, blister forming PVC film as specified
Aluminium foil: 0.025 mm, VMCH coated aluminium foil printed as per approved artwork
- b. One laminated kit will be required (either solely or adjuvant) with other essential drugs but kept separately) for each category of STI/RTI treatment as specified in schedule of requirement.
The kit will be in Blue colour and labelled as per details given under labels
Laminated material Glassine Paper (40gm) Aluminium(9um)/Poly (150 gauze)
Type of kit –Gusseted
Each kit will contain one (1) tablet each of Azithromycin 1 gram in Blister pack and 30 tablets doxycycline 100mg in blister pack kept separately each in the kit for use by one patient.
- c. Millboard/Grey Board box:
Board: at least 3mm corrugated cardboard is to be used, surrounded on inside and outside by tightly affix millboard of at least 400gsm.
Style of kit: Top and bottom tuck-in flap type.
The millboard box should be labelled with blue labels as given under para 9.4.5.3-Labels
Style of kit: Top and bottom tuck-in flap type.
The millboard box contains 20 kits and should be labelled in Blue colour as given under para 9.4.5.1-Labels
- d. Five ply shipper: Each shipper will contain 20milliboard/grey board/boxes and in Blue Colour labelled as per details given under labels 9.4.5.3.
Description: RSC(Universal), type-5ply corrugated box made in narrow flute from (150)5gsm, virgin quality 'A' grade Kraft paper.

STI/RTI KIT-5 Packing specification

- a. Blister packed drugs
PVC film: Transparent, food grade, blister forming PVC film as specified
Aluminium foil: 0.025 mm, VMCH coated aluminium foil printed as per approved artwork.
- b. One laminated kit will be required for STI/RTI treatment as per specified in the schedule of requirement.
The kit will be in Red colour and labelled as per details given under labels
Laminated material Glassine Paper (40gm) Aluminium (9um)/ Poly (150 gauze)
Type of kit –Gusseted
Each kit will contain twenty-one tablets of Acyclovir 400 mg for usage by one patient.
- c. Millboard/Grey Board box:
As given under labels
Board: at least 3mm corrugated cardboard is to be used, surrounded on inside and outside by tightly affix millboard of at least 400gsm.
Style of kit: Top and bottom tuck-in flap type.
Each red labelled millboard box contains 20kits and labelled as given under labels.
- d. Five ply shipper: Each shipper will contain 20milliboard/grey board/boxes and labelled in Red Colour as per details given under labels
Description: RSC(Universal), type-5ply corrugated box made in narrow flute from (150)5gsm, virgin quality 'A' grade Kraft paper.

STI/RTI KIT-6 Packing specification

- a. Blister packed drugs
PVC film: Transparent, food grade, blister forming PVC film as specified
Aluminium foil: 0.025 mm, VMCH coated aluminium foil printed as per approved artwork
- b. One laminated kit will be required for STI/RTI treatment as per specified in the schedule of requirement.
The kit will be in yellow colour and labelled as per details given under labels
Laminated material Glassine Paper (40gm) Aluminium (9um)/ Poly (150 gauze)
Type of kit –Gusseted
Each kit will contain one tablet of Azithromycin 1gm, twenty-eight tablets each of Doxycycline 100 mg and Metronidazole 400 mg all in their own blister packs and kept separately for usage by one patient.
- c. Millboard/Grey Board box:
Board: at least 3mm corrugated cardboard is to be used, surrounded on inside and outside by tightly affix millboard of at least 400gsm.
Style of kit: Top and bottom tuck-in flap type.
Each box contains 20kits and labelled as yellow colour as given under labels.
- d. Five ply shipper: Each shipper will contain 20milliboard/grey board/boxes and labelled in yellow Colour as per details given under labels
Description: RSC(Universal), type-5ply corrugated box made in narrow flute from (150)5gsm, virgin quality 'A' grade Kraft paper.

STI/RTI KIT-7 Packing specification

a. Blister packed drugs

PVC film: Transparent, food grade, blister forming PVC film as specified in 9.4.2
Aluminium foil: 0.025 mm, VMCH coated aluminium foil printed as per approved artwork

b. One laminated kit will be required (either solely or with adjunct with other essential drugs) for each category of STI/RTI treatment as per specified in the schedule of requirement.

The lot will be in Black colour and labelled as per details given under labels
Laminated material Glassine Paper (40gm) Aluminium (9um)/Poly (150 gauze)
Type of kit –Gusseted
Each kit will contain one tablet of Azithromycin 1gm and forty-two tablets Doxycycline 100 mg for usage by one patient.

c. Millboard/Grey Board in Black Colour

Labelled as given under labels
Board: at least 3mm corrugated cardboard is to be used, surrounded on inside and outside by tightly affix millboard of at least 400gsm.
Style of kit: Top and bottom tuck-in flap type.
Each black coloured millboard box contains 20kits and labelled as given under labels.

d. Five ply shipper: Each shipper will contain 20milliboard/grey board/boxes and labelled in yellow Colour as per details given under labels
Description: RSC(Universal), type - 5ply corrugated box made in narrow flute from (150)5gsm, virgin quality 'A' grade Kraft paper

Agenda 2:

Technical Specifications of Dual test kit for HIV & syphilis screening:

Background:

DDG BSD appraised the committee that on procurement proposal for Dual test kits for HIV & Syphilis screening for 2023-24 submitted by Basic Services and STI division, queries were raised by the Procurement division of NACO as follows:

- a. Confirmation that the technical specifications for Dual test kit HIV & syphilis is vendor neutral.
- b. Confirmation that the sufficient numbers of bidders would be available to participate.

It was informed to the committee that there are multiple manufacturers of this product and some points for discussion was flagged so as to make the specifications more clear and unambiguous, with respect to point no. 2 of technical specification on the term used "multiple antigen"; on applicability of the point no 3 regarding "clinical performance evaluation" and on kit controls at point 9 (c) .

2. "The assay should have following synthetic and/or recombinant antigens coated on solid phase"
 - a. Multiple *Treponema pallidum* antigens, and
 - b. Multiple Antigens of HIV 1 (including gp41) and HIV 2 (including gp36)"
 3. "The clinical performance evaluation data of the kit on whole blood sample should be made available by the manufacturer".
- 9 (c) The assay component should include sufficient amount of positive and negative controls.

After due deliberations and discussions, the committee decided to

- a) Modify the point 2 deleting the term "multiple" and also "antigens" and their description from the subpoints
- b) delete the point 3 mentioned above citing the view that the term Clinical performance evaluation is specifically meant for new IVD under medical devices rule 2017 and as such are covered under the regulatory framework

and do not need to be reiterated here. Programme could separately conduct a validation for use of these kits with whole blood sample with the support of National Reference Laboratories.

- c) Discussed regarding kit controls in point 9 subpoint c, and while retaining the specification, made it similar and specific in language along lines of specifications of HIV kit 1,2,3,4

The technical specification committee agreed to the revised technical specifications as follows by consensus: -

Technical Specifications of Dual test kit for HIV & syphilis is as follows:

1. The kit should be able to individually detect antibodies to HIV 1 & HIV 2 and Treponema pallidum by the rapid test, in human serum / plasma.
2. The assay should have following synthetic and/or recombinant antigens coated on solid phase
 - a. Treponema pallidum, and
 - b. HIV 1 and HIV 2
- 3.. The assay should be based on any of the rapid test principles such as flow-through (Immunoconcentration), or lateral flow (Immunochromatography).
4. The assay should have an in-built control for testing the validity of the test procedure.
5. The Control dot / band (in-built control), should be able to detect the presence of human immunoglobulins and should not merely check the flow of reagents or integrity of the antigen except for the kits based on the principle of lateral flow.
- 6.. The assay should have following performance characteristics:
 - a. For HIV, sensitivity of 100% and specificity $\geq 98\%$.
 - b. For Treponema pallidum, sensitivity $\geq 85\%$ and specificity $\geq 93\%$
- 7.. The time required for performing the test should not be more than 30 minutes.
- 8.. The kits should have a shelf life of 24 months, at least 5/6th of the minimum shelf life must remain at the time of dispatch to the consignee.
9. The manufacturer should ensure that:
 - a) The test device should be packed (along with the desiccant) such that there is a provision to conduct single test at a time.
 - b) The pack size of rapid test kits should be not more than 50 tests per kit.
 - c) The assay component should include sufficient volume of positive and negative controls for conducting 20% of the test as per the pack size.

- d) The kit should be supplied with a sufficient number of droppers to deliver the required amount of specimen as specified in the kit literature
11. Adequate documents detailing the principal components, details of antigen used / coated for detection of HIV 1 & 2 as well as Treponema pallidum antibodies, biosafety compliance, validity criteria, interpretation of results, performance characteristics, storage condition and limitation of assays should be provided, Also the manufacturing and expiry dates should be provided with each kit.
12. The manufacturer/authorized agent should ensure maintenance of cold chain during storage and transportation of the kits at 2 - 8' C. The cumulative time temperature indicator technology used should be pre-qualified by WHO.
13. Product should be licensed by the competent authority defined under Drugs & Cosmetic Act 1940 & Rule 1945 and / or medical devices rules 2017.

MAACCO

✓
ms
Gini

✓
h

Agenda 3: Technical specifications of Rubber Latex Condoms

Background:

NACO had issued the Condom Indent for the FY 2022-23 with the technical specification and art work of packing and labelling of condom as per usual practice. CMSS sought clarification from NACO in light of NACO specifications and Tender Bid Specifications being different as tabulated below.

Commodity	NACO Technical Specification	CMSS Bid Technical Specification
Rubber latex condom	<p>Dimensions. –</p> <p>(1) the length when unrolled (excluding teat) shall be not less than. -</p> <p>(i) 170mm</p> <p>(2) The width of a condom which laid flat and measured at any point within 85 mm from the open end shall be,</p> <p>(i) 49 ± 2mm for 170mm length</p>	<p>Dimensions:</p> <p>Length: the length when unrolled (excluding teat) shall be not less than 170mm with width 49+2mm measured as per details in part 2 below.</p> <p>Width: the width of a condom when laid flat and measured at any point within 85mm from the open end shall be;</p> <p>a. 49+2mm</p>
Quantity of condom Lubricant	<p>The condoms shall be dressed with silicone lubricant. The quantity required on each individual condom should not be less than 200 and minimum viscosity shall be 200 centistokes.</p>	<p>Quantity of lubricant- 250mg minimum Details of lubricant - Silicon Oil (Dimethyl Poly Siloxane) Viscosity - 200-350 CTSK Properties - Non-toxic and non-irritant to skin</p>

The technical specifications in use by NACO are a signed copy of extracts from Schedule R describing the “**Standards for condoms made of rubber latex intended for single use and other mechanical contraceptives**” from the Drugs and Cosmetics Rules and all procurements of condoms till date have been done using the same. However, in light of the discrepancies brought out on record, the matter has been placed before the Technical Specification Committee.

The technical specifications in the CMSS bid document were reviewed by the Committee and it was opined that since they meet the NACO specifications, the current procurements for NACO may be processed through the same in light of emergency.

During the meeting, inputs from the Family Planning division and RCH were also collated in terms of agreement. For future use, after thorough review and deliberations, the following specifications are approved by the Technical Specification Committee.

Technical Specifications of Latex Rubber Condom

1. **Description:**
Condom with teat end, lubricated for single use
Shelf Life of 3 years
2. **Lubrication and Lubricant:**
 - a. Quantity of lubricant - 250mg minimum
 - b. Details of lubricant - Silicon oil (DimethylPoly Siloxane)
 - c. Viscosity - 200-350 CTSK
 - d. Properties - Non-toxic and non-irritant to skin
3. **Dimensions**
 - i. Length: the length of condom when unrolled (excluding teat) shall be net less than 170mm
 - ii. Width: the width of a condom when laid flat and measured at any point within 85mm from the open end shall be;
 - a. 49 ± 2 mm
 - iii. Single wall thickness: the single wall thickness of a condom when measured at three points, one at 30 ± 2 mm from open end, 30 ± 5 mm from the closed and excluding the reservoir tip and at the mid distance between these two points shall be from 0.045mm to 0.075mm.

Handwritten initials/signature

Specifications of Labelling and Packaging:

1. Each (condom) of Free Supply Scheme is to be strip packed individually and 2 strip of each 5 foiled are to be packed in a polythene/ pouch of 150 gauge, duly printed with the various instructions required under Standards of Weights and Measures Act 1976 and rules made under the law.
2. The design and drawing of the polythene pouch should be in conformity with the artwork to be provided to the suppliers. " **Free Supply of Govt. Of India**

Handwritten signature

Handwritten signature

NOT FOR SALE AND NOT FOR EXPORT OUTSIDE INDIA' will be printed in indelible ink across each polythene pouch of Free Supply .

3a. STRIP : 4 Ply Laminated Foil

Material : 40/42 gsm GIP(glassine) paper/0.009mm aluminium foil / heat seal coating/Acid Copolymer of polythylene

Size of each strip : Strip size for squeeze pack, 70+2mm length x minimum 30mm width

A Type :

Printing : In 2 colours dark tan and red on one side only, as per artwork to be given to the suppliers. "Service fee leviable – RE 1 for 10 condoms" will be printed (instead of 'Free Supply' earlier.)

3b. CARTON : To contain 50 polythene pouches of 10 pcs. Each – total 500 pcs. in one carton. The words "Service fee of Re 1 for 10 condoms" will be printed (instead of 'not for sale').

Material : 450 gsm or above heavy duty gray board one side smooth surface to be used.

Printing : As on existing carton in red colour.

4. Specification for packing material for outer box

Narrow flute corrugated card board boxes of 7 ply, each ply of 150 gsm virgin Kraft paper of which outer ply to be alkali resistant (chemically treated of bituminised against white ants and other insects). Outer layer will be 60 + 40 + 60 gsm and corners reinforced with 3" wide gummed cloth tapes in dark tan colour as per write up as in previous supplies. Inside to be lined with polythene liner.

Each box should contain 12 cartons of 50 pouch x 10nos. of i.e.6000pcs.

As per above specification the total GSM is as follows:

Out of 7 piles 6 inner piles (1 to 6 piles)

150 gsm each - 900

7th out ply 160gsm x 1 - 160

Total - **1060**

Extra GSM for - 158

Corrugation of 3 piles

(@35%)

G.Total - **1218**

Bursting strength not less than 19 KGs/sq.cm.

5. Product should be licenced by competent authority defined under Drugs & cosmetic Act 1940 & Rule 1945 and / or medical Device Rules under 2017.




4 pieces Carton

Dr. Shashini Singh Kustiwal
Deputy Director
National AIDS Control Organization
Ministry of Health & F. W.
Govt. of India, New Delhi

AW No.	HLL/PT/170GH5/2002/Rev. 04/01/2021
Name	NACAO Wallet
Internal Dimension	58x80x23 mm LxBxH

197c
Black

22



AW No. HLL/PT/170GH5/2002/Rev. 04/01/2021
197c Black

AW No. HLL/PT/170GH5/2002/Rev. 04/01/2021

Dr. Shashini Singh Kustiwal
Deputy Director
National AIDS Control Organization
Ministry of Health & F. W.
Govt. of India, New Delhi

4023

23









[Handwritten signature]

[Handwritten signature]













 Deputy Director
 National AIDS Control Organization
 Ministry of Health & F. W.
 Govt. of India, New Delhi

INSTRUCTIONS FOR USE

 1. Take out the Condom from the packet, squeeze the closed end or tip of the condom slightly, holding between a finger and the thumb of one hand, to release the air.	 2. With the other hand, put the condom on the tip of the erected penis and unroll down the length by pushing down the rim of the condom.
 3. When the rim of the condom is at the base of the penis, penetration can begin.	 4. Immediately after the ejaculation, withdraw the penis while it is still hard, holding the rim of the condom to prevent it from slipping.
 5. Do not allow semen to spill on hands or other parts of the body.	 6. Wrap the used condom in waste paper before disposing it off safely.
 7. Always use a new condom, each time intercourse is repeated.	 8. Do not use oil-based lubricants like Vaseline, oil or cold cream as they may damage the condom.

उपयोग के निर्देश

 1. काण्डोम को पैकेट में से निकालिए, काण्डोम के अगले सिरे में से हवा निकालने के लिए उसे डैंगली और अंगूठे के बीच में पकड़ कर हल्के से दबाएँ और पकड़े रखिए।	 2. दूसरे हाथ से काण्डोम को उलटित सिरे के ऊपरी सिरे पर रखिए और काण्डोम के उलटने को धिमेसा कर खोलने हुए पूरे सिरे के ऊपर खना दीजिए।
 3. जब काण्डोम का छल्ला सिरे को जड़ तक पहुँच जाए तब (पॉनि में) प्रवेश कर सकते हैं।	 4. वीर्यस्राव के तुरंत बाद, जब सिरे कड़ा ही उसी दरमियान सिरे बाहर निकाल लीजिए, इस वक़्त काण्डोम का छल्ला पकड़े रखिए ताकि काण्डोम उतर न जाए।
 5. जीरे को हाथों या शरीर के अन्य अंगों या फैसले पर न डालिए।	 6. काण्डोम को सुरक्षा पूर्वक फेंकने से पहले रटी कागज़ में लपेट दीजिए।
 7. हर बार संभोग करते वक़्त नया काण्डोम इस्तेमाल कीजिए।	 8. तैलीय चिकनाई जैसे कि वैसलीन, तेल या क्रीम जोम इस्तेमाल मत कीजिए, उनसे काण्डोम खराब हो सकता है।


 Deputy Director
 National AIDS Control Organization
 Ministry of Health & F. W.
 Govt. of India, New Delhi

Handwritten signature

Handwritten signature

Handwritten signature

Handwritten signature

Note:




1. Name of the firm should be printed on the tape pasted on the cardboard for sealing purpose.
2. "Not for export outside India" must be printed on the wallet, cartons and corrugated cardboard boxes.
3. Leaflet illustrating how to use condoms must be enclosed in each pouch of ten condoms.
4. Condom width and length specification and that they comply to packaging must be mentioned on individual package (Wallets) and the cartons.
5. The identification mark like manufacturer's name (initials), year of production and scheme Free Supply/Social Marketing (F/S), as the case may be, would be screen printed on the condom itself within 5MM of the rim/open end of condom between the two dipping layers of latex during the manufacturing process.
6. The Batch No. would also be indicated in bar-code on the outer packaging in addition to its indication in the alpha numeric form.


Summary of the discussions:

1. The Technical specifications for pre-packaged colour coded STI/RTI drug kits were approved with minor modifications in consensus
2. The Technical specifications for Dual Test kit for HIV and Syphilis screening were approved with modifications in consensus.
3. The Technical specifications for Rubber Latex Condoms were formulated in consensus
4. No other matter was taken up during this meeting.

Meeting ended with vote of thanks to the chair.

List of Participants

S.no	Name	Designation and affiliation	Signature
1	Dr. Sunil Gupta	Principal Consultant, NCDC, New Delhi	
2	Dr. Sella Senthil	Asst. Drug Controller of India, CDSCO, Govt. of India, Delhi	
3	Dr. Rohit Chawala	Professor, Clinical Microbiology, MAMC, Delhi	concessance received via email
4	Dr. Rajesh K Sharma	Scientist Grade II, NIB, Noida	concessance received via email
5	Dr. Ashwini shete	Scientist 'E' Immunology & serology, NAARI, Pune	concessance received via email
6	Dr. Sumit Agrawal	Scientist 'C', Indian Council of Medical Research (ICMR) Delhi	concessance received via email
7	Dr. Shobini Rajan	Member Secretary, DDG (BSD & TI) NACO	
Experts:			
Agenda 1 : Pre Packed STI Colour Coded drugs kits			
8	Dr. Taru Garg	Director Professor, Lady Harding Hospital, Delhi	concessance received via email
9	Dr. Pankaj Rao	HoD, S,N. Medical College, Jodhpur (RJ)	concessance received via email
Experts:			
Agenda 2: Dual test kit for HIV & syphilis			
10	Dr. Sunil Sethi	Prof. PGI Chandigarh	concessance received via email
11	Dr. Sumathi Murlidhar	Professor & Microbiologist, Apex Regional STD Centre & SRL for HIV, Safdarjung, Delhi	concessance received via email
Experts:			
Agenda 3: Condom			
12	Dr. Govind Bansal	Director, RCH, MoHFW, Delhi	
13	Mr. Bipin Chandra Joshi	DD CSM, Delhi SACS	concessance received via email
14	Mr. Sunil Vishnoi	JD TI, Rajasthan SACS	concessance received via email



Compose

- Inbox 8
- Starred
- Snoozed
- Important
- Chats
- Sent
- Scheduled
- More

Labels +



8 of 10,961

Re: Draft RoD of Technical Specification Committee Meeting on 4 May 2023-reg.

D Sumathi Muralidhar

Dear Mr. Shailendra,

The draft RoD seems to be okay in general, but for some grammatical errors on some pages.

Best wishes,

Sumathi

On Monday, 8 May 2023 at 06:09:48 pm IST, Shailendra Gandharva <shailendra.nayak@gmail.com> wrote

Respected Ma'am/sr,

Re: Draft RoD of Technical Specification Committee Meeting on 4 May 2023-reg.

Inbox x



pankaj rao
to me ▾

11:55

Dear mr shailendra
I m fine with the changes incorporated in the draft.

Dr Pankaj Rao
Professor and Head of the department
Dr S N Medical College
Jodhpur

----- Forwarded message -----

From: **Shailendra Gandharva** <shailendra.naco@gmail.com>
Date: Fri, 12 May 2023, 11:30 am
Subject: Re: Draft RoD of Technical Specification Committee Meeting on 4 May 2023-reg
To: <dr.pankajrao83@gmail.com>
Cc: Dr Shobini Rajan <shobini.naco5@gmail.com>, <shobini.naco5@gmail.com>, Bhawani Singh <deputydirector.bs@gmail.com>, Deputy Director(STD <ddstdksans@gmail.com>), Vibhavan Deshmukh <vibhavan.naco@gmail.com>, Chaitanya Bhatt <chaitanya.naco@gmail.com>, samresh Kumar <samre <srivastava <saurabh.naco@gmail.com>, Thirunavukkarasu Murugan <thirunaco086@gmail.com>, <nyotsna.naco@gmail.com>, <suman.bsd.naco@gmail.com>, <arvindkumarnaco@gmail.com>, Hansa lala <hansalala.naco@gmail.com>, Abhishek Roval <abhishek.naco@nstu@gmail.com>, <navind.hansa178@nav.in>

Re: Draft RoD of Technical Specification Committee Meeting on 4 May 2023-reg. Inbox x



Dr. Rohit Chawla <rohitchawla75@gmail.com>

Thu, 11 May, 17:00

to Shailendra, Sunil, Sanjeev, Sumit, Director, Sheela, Samiran, Surander, Sumanthi, Manju, Taru, Delhi, Delhi, cst.delhisacs, Rajasthan, Rajasthan, ti.rsacs@gmail.cc

Dear Mr. Sahilendra,

The changes incorporated w.r.t. Dual Kit are fine with me

Regards,

Dr. Rohit Chawla

MBBS (MAMC, India), MD (Microbiology) (MAMC, India),

DNB (Microbiology) (Gold Medallist), D(ABMM) (USA),

FCCM (Canada), FRCPath-I (United Kingdom), CIC (USA)

MNAMS, MASM, DipRCPath

Professor

Department of Microbiology

Maulana Azad Medical College & Associated Hospitals

(Government of NCT of Delhi)

New Delhi-110002

INDIA

Ph: +91-9968604393, +91-9810079074

Re: Draft RoD of Technical Specification Committee Meeting on 4 May 2023-reg. inbox x

D Dr R K Sharma
to me

14:18 (27 minutes ago) ☆ ↶ ⋮

Sir,

The changes incorporated w.r.t. HIV & Syphilis Dual Kit seems OK.

Regards,

From: "shailendra naco" <shailendra.naco@gmail.com>
To: "Dr R K Sharma" <rksharma@nitb.gov.in>
Sent: Friday, May 12, 2023 12:10:53 PM
Subject: Re: Draft RoD of Technical Specification Committee Meeting on 4 May 2023-reg

Respected sir
Respected Ma'am sir,

I am grateful for your prompt inputs on the draft RoD of technical specification committee meeting held on 04th May 2023 and the same are incorporated in the RoD, the inputs are highlighted with blue & green for the ease of reading.

You are hereby requested to provide your concurrence by tomorrow evening, due to the urgency of the commodities, NACO has to take immediate action on the same.

The final version of the RoD is enclosed with the email, for your kind reference.

Thanks with regards,

Re: Draft RoD of Technical Specification Committee Meeting on 4 May 2023-reg. Inbox x

S

Sunil Sethi

to me, Sunil, Sanjeev, Sumit, Director, Sheela, Samiran, Surander, Sumanthi, Manju, Rohit, Taru, Delhi, Delhi, cst.delhisacs@gmail.com, Rajasthan, Rajasthan, trsacs@gmail.com, dr.pankajrao83@gmail.com

15:08 (4 minutes ago)

☆ ↶ ⋮

Dear Dr shailendra

I have concurrence with attached technical specifications
Best regards

Dr.Sunil Sethi MD,MXAMS.

Vice Chair South East Asia , IUSTI Asia Pacific

Nodal officer, STI Reference, Research & Training Centre & RNTCP Accredited TB Centre

Professor & In-Charge STD, TB & Serology division ,

Deptt of Medical Microbiology,PGIMER, Chandigarh,India 160012

Ph-91 1722755161 , 09872882609(Mobile) Fax-91 172 2744401

From: Shailendra Gandharva <shailendra.naco@gmail.com>

Sent: Thursday, May 11, 2023 4:40 PM

To: Dr. Sunil Gupta <drsuniigupta.nodc@gmail.com>; Dr. Sanjeev Kumar <dci@nic.in>; Dr. Sumit Agrawal <icmchqds@sansad.nic.in>; Director NARI <director@nariindia.org>; Dr. Sheela Godbole <sgodbole@nariindia.org>; Dr. Samiran panda <pandasamiran@gmail.com>; Dr. Surander Singh <info@nib.gov.in>; Dr. Sumanthi Murlidhar <sumu3579@yahoo.com>; Dr. Manju bala <manjubala_2@hotmail.com>; Dr. Rohit Chawala <rohitchawla75@gmail.com>; Dr. Taru Garg <tarugarg4@yahoo.co.in>; Delhi <delhisacs1@gmail.com>; Delhi <dsacs.ict@gmail.com>; cst.delhisacs@gmail.com <cst.delhisacs@gmail.com>; Rajasthan <rajasthanacs@gmail.com>; Rajasthan <jdbsrsacs1@gmail.com>; trsacs@gmail.com <trsacs@gmail.com>; dr.pankajrao83@gmail.com <dr.pankajrao83@gmail.com>; Lalitdaraiims@gmail.com <lalitdaraiims@gmail.com>; sunilsethi10@hotmail.com <sunilsethi10@hotmail.com>; ulidas.naco@gmail.com <ulidas.naco@gmail.com>; Dr Chinmoyee Das <drchinmoyee.naco@gmail.com>; BHAWNA RAO <drbhawna.naco@gmail.com>; Saiprasad Bhavsar <spbhavsar.nhs@yahoo.com>; Akanksha Bisht <abisht@nib.gov.in>; Dr Sumit Aggarwal <drsumitcmr@gmail.com>; dr.pankajrao83@gmail.com <dr.pankajrao83@gmail.com>; csm.dsacs@gmail.com <csm.dsacs@gmail.com>

Cc: Dr Shobini Rajan <shobini.naco5@gmail.com>; shobini.naco5@gmail.com <shobini.naco5@gmail.com>; Bhawani Singh <deputydirector.bs@gmail.com>; Deputy Director(STD) KSAPS <dstokksaps@gmail.com>; Vibhavari Deshmukh <vibhavari.naco@gmail.com>; Chaitanya Bhatt <chaitanya.naco@gmail.com>; samresh kumar <samresh.naco@gmail.com>; Saurabh Srivastava

Re: Draft RoD of Technical Specification Committee Meeting on 4 May 2023-reg. Inbox x



Dr. Ashwini Shete

to me ▾

16:13 (43 minutes ago) ☆ ↶

Dear Mr. Gandharva,

I hereby give my concurrence for the technical specifications revised as per the discussions during the Technical Specification Committee meeting held on 4 May 2023.
Thanks.

Dr. Ashwini Shete,
Scientist E,
Immunology and Serology,
ICMR-National AIDS Research Institute, Pune, India

On Fri, May 12, 2023 at 3:02 PM Shailendra Gandharva <shailendra.naco@gmail.com> wrote:

Respected Sir/Madam,

Greetings of the Day!


PFA for the RoD.

Thanks

Shailendra Gandharva

Associate Consultant
BSD, NACO

Re: Draft RoD of Technical Specification Committee Meeting on 4 May 2023-reg. » Inbox x



TI Division Rsacs

16:55 (3 minutes ago) ☆ ↶ ⋮

to Sunil, me, Sunil, Sanjeev, Sumit, Director, Sheela, Samiran, Surander, Samanthi, Manju, Rohit, Taru, Delhi, Delhi, cst.delhi@sacs, Rajasthan, Rajasthan, dr.pankajrao83, laltdaraima, ubdas.naco, Dr, BHAP

Dear sir

i have no issue with ROD of Technical Specification . OK from my side

Regards

Sunil Kumar

Joint Director

Officer /C Targeted Intervention

Rajasthan State AIDS Control Society , DMHS, JAIPUR

On Fri, May 12, 2023, 3:08 PM Sunil Sethi <sunilsethi10@hotmail.com> wrote:

Dear Dr shallandra

Re: Approved RoD of Technical Specification Committee Meeting on 4 May 2023-reg. Inbox x



taru garg <tarugarg4@yahoo.co.in>
to me ▾

Tue, 16 May, 17:31 (6 days ago) ☆ ↩

Thanks for sharing! Draft seems okay to me.

Thanks & Regards
Dr Taru Garg

[Sent from Yahoo Mail on Android](#)

On Mon, 15 May 2023 at 18:43, Shailendra Gandharva
<shailendra.naco@gmail.com> wrote:

Respected Ma'am/Sir,

Greetings of the day!

I would like to express my heartfelt gratitude for taking time to review & providing your prompt response on concurrence.

In regards to the completion of above said meeting & approval of RoD, i am sharing the final version of the reviewed & revised technical specifications of STI colour coded drug kits test kit for HIV & Syphilis and Condom.

Approved Record of Discussion for the same is enclosed herewith for your kind reference.

Thanks with regards,